ReviewJournal of pharmaceutical analysis2020
Current status of
Review in Journal of pharmaceutical analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Critical quality attributes of lipid nanoparticles andAsian journal of pharmaceutical sciences · 2025Review
- Lipid-Based Nanoparticles in Cancer Therapy: Advances in Targeted Drug Delivery and Therapeutic Potential for Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Flavonoid-Based Nanogels: A Comprehensive Overview.Gels (Basel, Switzerland) · 2025Review
- MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies.Military Medical Research · 2025Article
- Topical Delivery Systems for Plant-Derived Antimicrobial Agents: A Review of Current Advances.International journal of biomaterials · 2025Review
- Advanced bioanalytical techniques for pharmacokinetic studies of nanocarrier drug delivery systems.Journal of pharmaceutical analysis · 2025Review
- Niacinamide: a review on dermal delivery strategies and clinical evidence.Drug delivery and translational research · 2024Review
- Article
- Plumbagin Regulates Snail to Inhibit Hepatocellular Carcinoma Epithelial-Mesenchymal Transition in vivo and in vitro.Journal of hepatocellular carcinoma · 2024Article
- Review
- Preparation, characterization, and evaluation of the antitumor effect of kaempferol nanosuspensions.Drug delivery and translational research · 2023Article
- Emergence of Nano-Based Formulations for Effective Delivery of Flavonoids against Topical Infectious Disorders.Gels (Basel, Switzerland) · 2023Review
- Review
- pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy.Pharmaceutics · 2023Article
- Recent Advances in Antimicrobial Nano-Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2022Review
- Hyperspectral microscopy of subcutaneously released silver nanoparticles reveals sex differences in drug distribution.Micron (Oxford, England : 1993) · 2022Article
- Zein-based nano-delivery systems for encapsulation and protection of hydrophobic bioactives: A review.Frontiers in nutrition · 2022Review
- Nanomaterials Application in Endodontics.Materials (Basel, Switzerland) · 2021Review
- Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems.Pharmaceutics · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their unique physicochemical characteristics, such as prolonged circulation time, improved targeting and avoiding of drug-resistance. Despite the remarkable progress achieved over the last three decades, the understanding of the relationships between the in vivo pharmacokinetics of NDDSs and their safety profiles is insufficient. Analysis of NDDSs is far more complicated than the monitoring of small molecular drugs in terms of structure, composition and aggregation state, whereby almost all of the conventional techniques are inadequate for accurate profiling their pharmacokinetic behavior in vivo. Herein, the advanced bioanalysis for tracing the in vivo fate of NDDSs is summarized, including liquid chromatography tandem-mass spectrometry (LC-MS/MS), Förster resonance energy transfer (FRET), aggregation-caused quenching (ACQ) fluorophore, aggregation-induced emission (AIE) fluorophores, enzyme-linked immunosorbent assay (ELISA), magnetic resonance imaging (MRI), radiolabeling, fluorescence spectroscopy, laser ablation inductively coupled plasma MS (LA-ICP-MS), and size-exclusion chromatography (SEC). Based on these technologies, a comprehensive survey of monitoring the dynamic changes of NDDSs in structure, composition and existing form in system (i.e. carrier polymers, released and encapsulated drug) with recent progress is provided. We hope that this review will be helpful in appropriate application methodology for investigating the pharmacokinetics and evaluating the efficacy and safety profiles of NDDSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.